Abstract：
Asthma is a common chronic lung disease, and COVID-19 pandemic as a respiratory viral disease led to lung infection and resulted in millions of deaths. So, the impact of COVID-19 on asthma outcomes and the risk of being infected or hospitalized should be clarified. Systematic review and meta-analysis on the outcomes and risk of asthma for people with COVID-19 was done by searching electronic databases between 1 December 2019 and 31 July 2023. A total of 48 studies from 27 countries spread across all continents were included in the review. The prevalence of asthma among COVID-19 patients was 7.9%, and the analysis demonstrated a 16.5% reduction in the risk ratio for acquiring COVID-19 among subjects with asthma compared to those without asthma. There was no statistically significant difference in hospitalization risk, ICU admission risk, and death risk for COVID-19 patients with no asthma compared to those with asthma. The risk of death from COVID-19 was similar between nonasthmatics and asthmatics. The findings indicated that subjects with asthma may be at a lower risk of having infection with COVID-19 compared to those without asthma, but they have a similar risk of hospitalization and mortality.
摘要：
哮喘是一种常见的慢性肺部疾病,和COVID-19作为呼吸道病毒性疾病的大流行导致肺部感染，并导致数百万人死亡。所以,应明确COVID-19对哮喘结局的影响以及感染或住院的风险.通过搜索2019年12月1日至2023年7月31日之间的电子数据库，对COVID-19患者的哮喘结果和风险进行了系统评价和荟萃分析。来自遍布各大洲的27个国家的总共48项研究被纳入审查。COVID-19患者的哮喘患病率为7.9%,分析表明,与无哮喘的受试者相比,有哮喘的受试者获得COVID-19的风险比降低了16.5%.住院风险差异无统计学意义，ICU入院风险，与无哮喘的COVID-19患者相比，无哮喘的COVID-19患者的死亡风险。非哮喘患者和哮喘患者死于COVID-19的风险相似。研究结果表明，与没有哮喘的受试者相比，患有哮喘的受试者感染COVID-19的风险可能更低，但他们有相似的住院和死亡风险。
